Veterinary applications of induced pluripotent stem cells

Regenerative medicine and models for disease?

Alberto Cebrian-Serrano, Tom Stout, A. Dinnyés

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Induced pluripotent stem cells (iPSCs) can now be derived from a tissue biopsy and represent a promising new platform for disease modelling, drug and toxicity testing, biomarker development and cell-based therapies for regenerative medicine. In regenerative medicine, large animals may represent the best models for man, and thereby provide invaluable systems in which to test the safety and the potential of iPSCs. Hence, testing iPSCs in veterinary species may serve a double function, namely, developing therapeutic products for regenerative medicine in veterinary patients while providing valuable background information for human clinical trials. The production of iPSCs from livestock or wild species is attractive because it could improve efficiency and reduce costs in various fields, such as transgenic animal generation and drug development, preservation of biological diversity, and because it also offers an alternative to xenotransplantation for in vivo generation of organs. Although the technology of cellular reprogramming using the so-called 'Yamanaka factors' is in its peak expectation phase and many concerns still need to be addressed, the rapid technical progress suggests that iPSCs could contribute significantly to novel therapies in veterinary and biomedical practice in the near future. This review provides an overview of the potential applications of iPSCs in veterinary medicine.

Original languageEnglish
Pages (from-to)34-42
Number of pages9
JournalVeterinary Journal
Volume198
Issue number1
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Induced Pluripotent Stem Cells
Regenerative Medicine
disease models
medicine
therapeutics
veterinary medicine
xenotransplantation
drugs
Heterologous Transplantation
transgenic animals
Genetically Modified Animals
Veterinary Medicine
Biodiversity
Livestock
Cell- and Tissue-Based Therapy
toxicity testing
Drug-Related Side Effects and Adverse Reactions
induced pluripotent stem cells
biopsy
clinical trials

Keywords

  • Animal models
  • Induced pluripotent stem cell
  • Regenerative medicine
  • Reprogramming
  • Veterinary

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)

Cite this

Veterinary applications of induced pluripotent stem cells : Regenerative medicine and models for disease? / Cebrian-Serrano, Alberto; Stout, Tom; Dinnyés, A.

In: Veterinary Journal, Vol. 198, No. 1, 10.2013, p. 34-42.

Research output: Contribution to journalArticle

@article{5a4dac6fc4ac4fd1a83acbc7ec4f5033,
title = "Veterinary applications of induced pluripotent stem cells: Regenerative medicine and models for disease?",
abstract = "Induced pluripotent stem cells (iPSCs) can now be derived from a tissue biopsy and represent a promising new platform for disease modelling, drug and toxicity testing, biomarker development and cell-based therapies for regenerative medicine. In regenerative medicine, large animals may represent the best models for man, and thereby provide invaluable systems in which to test the safety and the potential of iPSCs. Hence, testing iPSCs in veterinary species may serve a double function, namely, developing therapeutic products for regenerative medicine in veterinary patients while providing valuable background information for human clinical trials. The production of iPSCs from livestock or wild species is attractive because it could improve efficiency and reduce costs in various fields, such as transgenic animal generation and drug development, preservation of biological diversity, and because it also offers an alternative to xenotransplantation for in vivo generation of organs. Although the technology of cellular reprogramming using the so-called 'Yamanaka factors' is in its peak expectation phase and many concerns still need to be addressed, the rapid technical progress suggests that iPSCs could contribute significantly to novel therapies in veterinary and biomedical practice in the near future. This review provides an overview of the potential applications of iPSCs in veterinary medicine.",
keywords = "Animal models, Induced pluripotent stem cell, Regenerative medicine, Reprogramming, Veterinary",
author = "Alberto Cebrian-Serrano and Tom Stout and A. Dinny{\'e}s",
year = "2013",
month = "10",
doi = "10.1016/j.tvjl.2013.03.028",
language = "English",
volume = "198",
pages = "34--42",
journal = "Veterinary Journal",
issn = "1090-0233",
publisher = "Bailliere Tindall Ltd",
number = "1",

}

TY - JOUR

T1 - Veterinary applications of induced pluripotent stem cells

T2 - Regenerative medicine and models for disease?

AU - Cebrian-Serrano, Alberto

AU - Stout, Tom

AU - Dinnyés, A.

PY - 2013/10

Y1 - 2013/10

N2 - Induced pluripotent stem cells (iPSCs) can now be derived from a tissue biopsy and represent a promising new platform for disease modelling, drug and toxicity testing, biomarker development and cell-based therapies for regenerative medicine. In regenerative medicine, large animals may represent the best models for man, and thereby provide invaluable systems in which to test the safety and the potential of iPSCs. Hence, testing iPSCs in veterinary species may serve a double function, namely, developing therapeutic products for regenerative medicine in veterinary patients while providing valuable background information for human clinical trials. The production of iPSCs from livestock or wild species is attractive because it could improve efficiency and reduce costs in various fields, such as transgenic animal generation and drug development, preservation of biological diversity, and because it also offers an alternative to xenotransplantation for in vivo generation of organs. Although the technology of cellular reprogramming using the so-called 'Yamanaka factors' is in its peak expectation phase and many concerns still need to be addressed, the rapid technical progress suggests that iPSCs could contribute significantly to novel therapies in veterinary and biomedical practice in the near future. This review provides an overview of the potential applications of iPSCs in veterinary medicine.

AB - Induced pluripotent stem cells (iPSCs) can now be derived from a tissue biopsy and represent a promising new platform for disease modelling, drug and toxicity testing, biomarker development and cell-based therapies for regenerative medicine. In regenerative medicine, large animals may represent the best models for man, and thereby provide invaluable systems in which to test the safety and the potential of iPSCs. Hence, testing iPSCs in veterinary species may serve a double function, namely, developing therapeutic products for regenerative medicine in veterinary patients while providing valuable background information for human clinical trials. The production of iPSCs from livestock or wild species is attractive because it could improve efficiency and reduce costs in various fields, such as transgenic animal generation and drug development, preservation of biological diversity, and because it also offers an alternative to xenotransplantation for in vivo generation of organs. Although the technology of cellular reprogramming using the so-called 'Yamanaka factors' is in its peak expectation phase and many concerns still need to be addressed, the rapid technical progress suggests that iPSCs could contribute significantly to novel therapies in veterinary and biomedical practice in the near future. This review provides an overview of the potential applications of iPSCs in veterinary medicine.

KW - Animal models

KW - Induced pluripotent stem cell

KW - Regenerative medicine

KW - Reprogramming

KW - Veterinary

UR - http://www.scopus.com/inward/record.url?scp=84887615233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887615233&partnerID=8YFLogxK

U2 - 10.1016/j.tvjl.2013.03.028

DO - 10.1016/j.tvjl.2013.03.028

M3 - Article

VL - 198

SP - 34

EP - 42

JO - Veterinary Journal

JF - Veterinary Journal

SN - 1090-0233

IS - 1

ER -